Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. | Zendy

Rafał Turo | Zendy; Samer Jallad | Zendy; William Cross | Zendy; Stephen M. Prescott | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.

Author(s) -

Rafał Turo,

Samer Jallad,

William Cross,

Stephen M. Prescott

Publication year - 2013

Publication title -

canadian urological association journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.477

H-Index - 38

eISSN - 1920-1214

pISSN - 1911-6470

DOI - 10.5489/cuaj.175

Subject(s) - medicine , prostate cancer , transsexual , transgender , incidence (geometry) , cancer , prostate , estrogen therapy , hormonal therapy , disease , hormone therapy , estrogen , oncology , gynecology , breast cancer , psychology , physics , psychoanalysis , optics

The incidence of prostate cancer in transsexual patients is very low with only few reported cases. Many years before presenting with prostate cancer, these patients receive hormone ablation as a part of their gender therapy. Their disease is already defined as castrate resistant, and the treatment and follow-up of such patients remains a challenge. We report a case of a male-to-female transgender woman who was diagnosed with metastatic prostate cancer, 31 years post-feminization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research